FDA grants fast review to BMS’ first-line lung cancer comboBristol-Myers Squibb has finally made its bid for a slice of the lucrative first-line lung non-small cell lung Share XFDA grants fast review to BMS’ first-line lung cancer combohttps://pharmaphorum.com/news/fda-grants-fast-review-to-bms-first-line-lung-cancer-combo/
Nektar pulls pain drug after bruising FDA panel meetingNektar Therapeutics has opted to withdraw its marketing application for new opioid painkiller oxycodegol after an FDA advisory Share XNektar pulls pain drug after bruising FDA panel meetinghttps://pharmaphorum.com/news/nektar-pulls-pain-drug-after-bruising-fda-panel-meeting/
GSK has no immediate plans to spin off Pfizer joint ventureGlaxoSmithKline has made no plans to spin off or float its consumer healthcare joint venture with Pfizer, according Share XGSK has no immediate plans to spin off Pfizer joint venturehttps://pharmaphorum.com/news/gsk-spin-off-pfizer-joint-venture/
Oviva raises $21m for digital tool to help reverse diabetesSwiss digital therapy specialist Oviva has raised $21 million in second-round financing to help expand the use of Share XOviva raises $21m for digital tool to help reverse diabeteshttps://pharmaphorum.com/news/oviva-raises-21m-for-digital-tool-to-help-reverse-diabetes/
Clovis takes PARP prostate cancer pole position with fast FDA review of RubracaThe FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate Share XClovis takes PARP prostate cancer pole position with fast FDA review of Rubracahttps://pharmaphorum.com/news/clovis-takes-parp-prostate-cancer-pole-position-with-fast-fda-review-of-rubraca/
Syneos Health invests in Microsoft/Indegene platformBiopharma services company Syneos Health has taken a minority stake in Indegene Omnipresence, a partnership between life sciences Share XSyneos Health invests in Microsoft/Indegene platformhttps://pharmaphorum.com/news/syneos-health-microsoft-indegene-life-sciences-platform/
OPEN Health launches new Learning & Development specialist teamOPEN Health has launched a new specialist Learning & Development (L&D) team that will further expand its existing Share XOPEN Health launches new Learning & Development specialist teamhttps://pharmaphorum.com/sales-marketing/open-health-launches-new-learning-development-specialist-team/
UK accounts for 12% of cell and gene therapy trials – reportThe UK accounts for over 12% of global cell and gene therapy clinical trials, according to new data Share XUK accounts for 12% of cell and gene therapy trials – reporthttps://pharmaphorum.com/news/uk-accounts-for-12-of-cell-and-gene-therapy-trials-report/
ViiV’s two-drug HIV therapy Dovato gets Japanese approvalOne of ViiV Healthcare’s two-drug HIV therapies – Dovato – has been approved in Japan, providing a new Share XViiV’s two-drug HIV therapy Dovato gets Japanese approvalhttps://pharmaphorum.com/news/viivs-two-drug-hiv-therapy-dovato-gets-japanese-approval/
